NEJM This Week — August 20, 2026
Summary
This episode covers trials showing mucoactive agents harm ICU patients and azithromycin fails for preschool wheezing, while sunvozertinib and cervodotide show promise for lung cancer and obesity. It reviews myeloproliferative neoplasms and a case of disseminated CMV and cryptococcus in myasthenia gravis. Perspectives address marijuana rescheduling, AI automation risks, SGM health research cuts, and the Perspectives Editor’s retirement.
Topics discussed
Introduction and episode overview
Mucoactive agents in acute respiratory failure
Azithromycin for preschool wheezing
Sunvozertinib for NSCLC with EGFR mutations
Cervodotide for obesity treatment
Review of myeloproliferative neoplasms
Case: Myasthenia gravis and disseminated infections
Perspective: Marijuana rescheduling and research
Perspective: AI automation paradox in clinical care
Perspective: Impact of ending SGM health research
Perspective: Farewell to editor Deborah Molina
Images in clinical medicine: Malaria, Lupus, and Arthropathy
Listen ad-free on Castria